FDA Peptide Reclassification 2026: Which Peptides Are Under Review and What Changes

What Is the PCAC and Why Does This Meeting Matter?

The Pharmacy Compounding Advisory Committee is a standing FDA advisory body that evaluates active pharmaceutical ingredients (APIs) for inclusion on the 503A Bulks List — the list of bulk drug substances that licensed compounding pharmacies may legally use to prepare medications for individual patients with valid prescriptions. The committee reviews each candidate against four criteria laid out in Section 503A(b)(1)(A)(i) of the Federal Food, Drug, and Cosmetic Act: physical and chemical characterization, safety, evidence of effectiveness, and historical use in compounding.

PCAC outcomes are advisory recommendations to the FDA, not final rulings. A positive vote does not automatically place a peptide on the list. A negative vote does not by itself ban it. The agency typically converts PCAC recommendations into Federal Register rulemaking over the following 12 to 24 months — first a proposed rule, then a public comment window, then a final rule. By that path a July 2026 vote points to a likely formal outcome in late 2026 or 2027. Meeting materials and the official agenda are posted on the FDA advisory committee calendar at fda.gov.

The July 2026 meeting matters because it is the first time the PCAC reviews this slate of peptides in a single docket. The compounded-peptide market expanded significantly during the GLP-1 shortage years, and the agency is now tightening the framework. The same regulatory cycle that produced the April 30, 2026 proposed 503B exclusion of semaglutide, tirzepatide, and liraglutide is now reaching the 503A peptide list — with implications for clinics, compounders, and US patients who rely on compounded peptide protocols.

Day 1 — July 23, 2026: BPC-157, TB-500, MOTS-c, KPV

Day 1 covers four peptides framed around tissue repair, regeneration, and metabolic indications. The FDA docket evaluates each compound as the free base and the acetate salt where applicable, because compounders sometimes source one form and substitute the other based on stability or supplier availability.

BPC-157 — Use Under Review: Ulcerative Colitis

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a 15-amino-acid fragment of a protein found in human gastric juice. Preclinical literature, primarily from a small group of laboratories in Croatia, reports effects on angiogenesis, tendon and ligament healing, and gastrointestinal tissue repair. The PCAC docket evaluates the indication of ulcerative colitis, the use with the deepest historical compounding signal.

The evidence picture is contested. A February 3, 2026 STAT News investigation argued the published BPC-157 literature is concentrated in a narrow author network with limited independent replication and minimal controlled human data. A Phase 2 randomized controlled trial registered as NCT07437547 is enrolling, and the NCBI PMC review at PMC12446177 catalogues mechanisms across rodent injury models. As of May 2026, BPC-157 has no approved indication in any jurisdiction. The 503A vote is therefore a question of historical compounding use plus the strength of the available preclinical record, not approved therapeutic status.

TB-500 — Use Under Review: Wound Healing

TB-500 is a synthetic 17-amino-acid fragment derived from Thymosin Beta-4 (Tβ4), a naturally occurring regulatory peptide implicated in actin sequestration, cell migration, and angiogenesis. The PCAC reviews TB-500 for wound healing. Orthopaedic and dermatologic compounding has been the primary historical use; the PMC12753158 orthopaedic review surveys preclinical and pilot human data.

Like BPC-157, TB-500 lacks any FDA-approved indication. The Day 1 committee discussion is expected to focus on assay variability between TB-500 (the fragment) and full Thymosin Beta-4, since compounders have at times sourced one and labeled the other. Identity and characterization sit at the centre of the 503A bulks calculus, ahead of efficacy.

MOTS-c — Uses Under Review: Obesity and Osteoporosis

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome. The PCAC docket evaluates two indications: obesity and osteoporosis. Preclinical work, including the mechanism paper indexed as PMID 41520850, links MOTS-c to AMPK activation, insulin sensitivity, and bone-cell signaling.

MOTS-c sits in a different regulatory category than BPC-157 or TB-500. The compounding history is shorter and the published human data thinner, which historically weighs against 503A inclusion. The committee will likely focus on whether a stable manufacturing and identity standard exists for the peptide, since synthesis and storage parameters for mitochondrial-derived peptides remain less standardized than for traditional therapeutic peptides.

KPV (Lys-Pro-Val) — Uses Under Review: Wound Healing and Inflammatory Conditions

KPV is a tripeptide (Lys-Pro-Val) corresponding to the C-terminal tripeptide of α-MSH (alpha-melanocyte-stimulating hormone). Preclinical models describe anti-inflammatory effects in colitis and skin inflammation, and KPV has appeared in topical compounding for dermatologic and gastrointestinal applications. The PCAC reviews the indications of wound healing and inflammatory conditions.

As a short peptide, KPV is easier to characterize chemically than BPC-157 or TB-500, which works in its favour on the identity criterion. Whether the published efficacy and safety record is sufficient to support 503A inclusion remains the contested question.

Day 2 — July 24, 2026: Semax, Epitalon, DSIP

Day 2 covers three peptides oriented around neurological and sleep-related indications. The compounding history concentrated in nootropic clinics and longevity-focused practices is the policy backdrop.

Semax — Uses Under Review: Cerebral Ischemia, Migraine, Trigeminal Neuralgia

Semax is a heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-7) with an extended C-terminal proline-glycine-proline sequence. Originally developed in Russia, Semax has appeared in regional therapeutic use for cerebrovascular and neurological indications. The PCAC reviews cerebral ischemia, migraine, and trigeminal neuralgia — each evaluated for the free base and acetate forms.

The published clinical literature on Semax is predominantly Russian-language and dates from regional clinical practice rather than FDA-aligned trials. For a 503A bulks decision, the committee weighs whether that body of evidence meets the “recognized historical use in compounding” criterion under US conditions.

Epitalon / Epithalon — Use Under Review: Insomnia

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed in Russia and studied for its proposed effects on melatonin synthesis, telomerase activity, and pineal-gland signaling. The PCAC reviews the indication of insomnia, with the free base and acetate forms evaluated separately.

Epitalon’s research literature shares the Semax profile: a regional clinical and gerontology record concentrated in a small number of institutions, with limited replication in independent Western trials. The 503A decision is therefore about the strength of US compounding use plus identity and assay standards, not about pivotal trial efficacy.

DSIP / Emideltide — Uses Under Review: Opioid Withdrawal, Chronic Insomnia, Narcolepsy

DSIP (Delta Sleep-Inducing Peptide), referred to in the PCAC docket under the name Emideltide for the proposed compounded form, is a nonapeptide originally isolated from rabbit cerebral venous blood and named for its effect on EEG delta-wave activity. The PCAC reviews three indications: opioid withdrawal, chronic insomnia, and narcolepsy.

DSIP/Emideltide has the broadest indication slate of the seven peptides on the docket, and also one of the longest historical compounding records in the sleep and addiction-medicine niches. The breadth of indications cuts both ways: it gives the compounding side multiple use-history threads to point to, but it also gives the committee multiple efficacy questions to evaluate before voting on inclusion.

What “PCAC Review” Means in Practice

The PCAC vote is one step in a multi-stage regulatory cycle. The mechanical sequence is consistent across compounded peptide reviews:

1. FDA docket and meeting materials published in advance on the advisory committee calendar.
2. Public meeting — presentations by FDA staff, industry stakeholders, and clinicians; open comment period; committee deliberation; advisory vote on each candidate.
3. FDA review of PCAC recommendation — weeks to months, during which the agency drafts proposed rulemaking aligned with or departing from the committee’s advisory vote.
4. Federal Register proposed rule — the FDA’s formal position on inclusion or exclusion is published, opening a public comment window (typically 60 to 90 days).
5. Final rule — after comment review, the FDA publishes the binding determination. Inclusion or exclusion takes legal effect on the date the final rule is enforceable.

Inclusion on the 503A Bulks List allows licensed compounding pharmacies in the United States to use the peptide as an active pharmaceutical ingredient when preparing patient-specific prescriptions. The peptide remains unapproved as a finished drug — there is still no brand-name product on the US market — but the compounding pathway becomes available with documented sourcing and prescriber oversight. Exclusion blocks that pathway. The FDA Law Blog provides a useful primer on the broader 503A/503B compounding landscape at thefdalawblog.com, and OptiMantra covers the Category 2 shift context.

The 503B Bulks Exclusion Proposal in Context

The PCAC peptide review does not happen in isolation. On April 30, 2026, the FDA proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the parallel list governing outsourcing facilities that compound at scale. Reuters reported the proposal at reuters.com. The proposed exclusion closes the compounded GLP-1 lane that expanded during the 2022 to 2024 shortage period.

Three weeks later, on May 18, 2026, SafeMedicines published a warning about illicit distribution tied to ProRx, naming companies operating outside the regulatory framework for compounded GLP-1 and peptide product. The full warning is at safemedicines.org.

Read together, the April 30 proposed rule and the May 18 enforcement notice show an enforcement curve, not isolated incidents. The PCAC peptide review on July 23-24 fits the same regulatory direction: the agency is moving to formalize and tighten the rules governing compounded peptide product across both the 503A and 503B pathways. That context matters for how to read the upcoming vote. A skeptical PCAC stance on any of the seven peptides on the docket would be consistent with the broader 2026 enforcement signal.

What This Means for Researchers and Clinics

For US compounding pharmacies and clinics, the practical takeaway is that the legal status of all seven peptides could shift between July 2026 and late 2027. The change comes through Federal Register rulemaking, not the PCAC vote itself, but the vote is the leading indicator. Compounders that build protocols around BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon, or DSIP need to be tracking the rulemaking timeline now.

For US researchers studying these compounds in academic or industry-sponsored settings, the PCAC process does not directly govern preclinical or clinical research. Investigator-initiated trials and IND-enabled studies continue under their own framework. The bulks list is a compounding-supply question; the research lane is a separate regulatory track.

International and UAE context. Under UAE MoHAP Circular 17/2022, research-grade peptides are available in the UAE for in-vitro laboratory research only — not for prescription, clinical, or human therapeutic use. US 503A and 503B determinations do not change UAE research-use supply. A negative PCAC vote on, say, BPC-157 does not block UAE laboratory study of the same compound under research-use compliance. A positive vote does not unlock US therapeutic use either — it only opens the 503A compounding pathway for patient-specific prescriptions. The frameworks operate independently.

For the broader UAE peptide landscape and how research-use compliance interacts with current GLP-1 and metabolic peptide research, see our peptide trends in the UAE 2026 analysis and the peptide legality guide for Dubai.